Abeona Therapeutics Net Income vs. Shares Owned By Insiders

ABEO Stock  USD 5.98  0.06  1.01%   
Based on Abeona Therapeutics' profitability indicators, Abeona Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Abeona Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1995-12-31
Previous Quarter
7.4 M
Current Value
-30.3 M
Quarterly Volatility
9.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of the 11th of December 2024, Sales General And Administrative To Revenue is likely to grow to 10.49, while Price To Sales Ratio is likely to drop 29.07. At this time, Abeona Therapeutics' Income Tax Expense is very stable compared to the past year. As of the 11th of December 2024, Non Operating Income Net Other is likely to grow to about 1.8 M, while Accumulated Other Comprehensive Income is likely to drop (69.3 K).
For Abeona Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Abeona Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Abeona Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Abeona Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Abeona Therapeutics over time as well as its relative position and ranking within its peers.
  

Abeona Therapeutics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.38)
Return On Equity
(1.27)
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Abeona Therapeutics Shares Owned By Insiders vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Abeona Therapeutics's current stock value. Our valuation model uses many indicators to compare Abeona Therapeutics value to that of its competitors to determine the firm's financial worth.
Abeona Therapeutics is rated below average in net income category among its peers. It is rated below average in shares owned by insiders category among its peers . Abeona Therapeutics reported last year Net Loss of (54.19 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Abeona Therapeutics' earnings, one of the primary drivers of an investment's value.

Abeona Shares Owned By Insiders vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Abeona Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(54.19 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Abeona Therapeutics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
5.10 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Abeona Shares Owned By Insiders Comparison

Abeona Therapeutics is currently under evaluation in shares owned by insiders category among its peers.

Abeona Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Abeona Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Abeona Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Abeona Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Abeona Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-66 K-69.3 K
Operating Income-47.1 M-44.8 M
Income Before Tax-54.2 M-51.5 M
Net Loss-54.2 M-51.5 M
Total Other Income Expense Net-7.1 M-6.7 M
Income Tax ExpenseM3.2 M
Net Loss-54.2 M-56.9 M
Non Operating Income Net Other1.7 M1.8 M
Net Loss-39.1 M-41.1 M
Interest Income2.1 M1.2 M
Net Interest Income1.7 M1.8 M
Change To Netincome38 M39.9 M
Net Loss(2.53)(2.66)
Income Quality 0.68  0.95 
Net Income Per E B T 0.72  0.56 

Abeona Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Abeona Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Abeona Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Abeona Therapeutics' important profitability drivers and their relationship over time.

Use Abeona Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abeona Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abeona Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Abeona Therapeutics Pair Trading

Abeona Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Abeona Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abeona Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abeona Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abeona Therapeutics to buy it.
The correlation of Abeona Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abeona Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abeona Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abeona Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Abeona Therapeutics position

In addition to having Abeona Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Military Industrial Thematic Idea Now

Military Industrial
Military Industrial Theme
A collection of large United States defense contractors including companies involved in production or distribution of aircraft, ships, vehicles, weaponry, and electronic systems in cooperation with the government. The Military Industrial theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Military Industrial Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock:
Check out Trending Equities.
To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
To fully project Abeona Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Abeona Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Abeona Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Abeona Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Abeona Therapeutics investors may work on each financial statement separately, they are all related. The changes in Abeona Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Abeona Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.